Educational guide
Adipotide (FTPP): Dosage, Benefits, FDA Status & Clinics
What Is Adipotide (FTPP)? Adipotide — also called FTPP, short for Phe-Arg-Phe-Phe-Ala-Arg-Lys-Leu-Ala-Lys-Leu-Ala-Lys-Lys-Ala-Leu-Ala-Lys-Leu-Ala-Lys-Ala-Ala-Lys-Lys — is a synthetic proapoptotic peptide designed to do something no other weight loss compound a
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
What Is Adipotide (FTPP)?
Adipotide — also called FTPP, short for Phe-Arg-Phe-Phe-Ala-Arg-Lys-Leu-Ala-Lys-Leu-Ala-Lys-Lys-Ala-Leu-Ala-Lys-Leu-Ala-Lys-Ala-Ala-Lys-Lys — is a synthetic proapoptotic peptide designed to do something no other weight loss compound attempts: destroy the blood vessels that feed fat tissue, causing adipose deposits to literally starve and shrink. That's not a metaphor. The mechanism is vascular ablation targeted specifically at white adipose tissue.
The research behind it produced genuinely striking results in obese rhesus monkeys — animals whose metabolic physiology is close enough to humans that the data got real attention. But Adipotide has never been tested in a human clinical trial, and the reason is kidney toxicity. The same aggressive mechanism that kills fat-feeding blood vessels also causes measurable kidney damage in primates. That's where the story currently stalls.
If you're reading this because you've seen Adipotide marketed online or discussed in peptide communities, here's what you need to know: the compound exists, the early animal data is real, and the kidney risk is also real. This page covers all of it.
Adipotide targets prohibitin receptors on blood vessels feeding white adipose tissue, triggering apoptosis (programmed cell death) in those vessels and causing fat tissue to shrink — a mechanism unlike any approved weight loss drug.